TDP43 M337V

TDP-43 (TAR DNA-binding protein 43) is an RNA-binding protein essential for RNA metabolism, splicing, and transport within cells. Under normal conditions, TDP-43 resides primarily in the cell nucleus, but in ALS and FTD, it mislocalizes to the cytoplasm where it forms toxic aggregates that are found in approximately 97% of ALS cases and 45% of FTD cases [4]. The M337V mutation, where methionine at position 337 is replaced by the smaller amino acid valine, is located in the C-terminal domain (CTD), a region critical for protein phase transitions and aggregation behavior [5]. Recent research demonstrates that M337V significantly exacerbates TDP-43 proteotoxicity compared to wild-type protein, increasing oxidative stress and neuronal injury in motor neuron-like cells [1]. This mutation appears to enhance the protein's tendency to undergo aberrant phase transitions, shifting from normal liquid-like assemblies to pathological solid aggregates [3]. The C-terminal alpha-helix region where M337V resides plays a crucial role in coupling condensate formation (normal cellular assemblies) with amyloid assembly (disease-related fibrils), and mutations in this region can uncouple these processes [5]. The AlphaFold2 structure prediction for M337V yielded an average confidence score (pLDDT) of 65.7, which falls into the low-confidence range (below 70). This moderate-to-low confidence reflects the inherent disorder of TDP-43's C-terminal domain, which lacks a stable fixed structure under physiological conditions. The CTD is intrinsically disordered, meaning it exists as an ensemble of flexible conformations rather than a single rigid shape [5]. Therefore, the low confidence scores should be interpreted not as prediction failure, but as accurately capturing the dynamic, disordered nature of this protein region. Definitive structural conclusions about mutation-specific conformational changes cannot be made with confidence at this resolution. The molecular consequences of M337V extend beyond simple structural changes. The mutation occurs in a region where TDP-43 interacts with multiple cellular quality control systems. Studies show that TRIM16, a protein involved in cellular stress responses, is downregulated in cells expressing M337V, leading to impaired activation of antioxidant defenses and increased oxidative injury [1]. Additionally, TDP-43 mutations can influence interactions with other ALS-associated proteins like SOD1, potentially amplifying disease mechanisms through multiple pathways [2]. The mutation's location in the CTD may also affect nuclear-cytoplasmic transport dynamics, which modulate TDP-43's phase behavior and aggregation propensity [3]. Clinically, M337V represents one of several pathogenic variants in TDP-43's C-terminal region associated with familial ALS and FTD. The mutation contributes to the broader landscape of TDP-43 proteinopathies, which also include cases caused by mutations in other genes and sporadic disease. Recent advances in biomarker development, such as CSF acetylated tau measurements, are improving the ability to distinguish between TDP-43 and tau pathology in living patients [4], though direct detection of specific TDP-43 mutations in biofluids remains challenging. Understanding mutation-specific effects like those of M337V may inform future precision medicine approaches, particularly as therapeutic strategies targeting TDP-43 aggregation and phase behavior advance toward clinical testing.